惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

V
Visual Studio Blog
量子位
大猫的无限游戏
大猫的无限游戏
Hugging Face - Blog
Hugging Face - Blog
S
SegmentFault 最新的问题
Blog — PlanetScale
Blog — PlanetScale
月光博客
月光博客
Google DeepMind News
Google DeepMind News
小众软件
小众软件
WordPress大学
WordPress大学
宝玉的分享
宝玉的分享
MongoDB | Blog
MongoDB | Blog
B
Blog RSS Feed
博客园 - Franky
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
B
Blog
博客园 - 聂微东
The GitHub Blog
The GitHub Blog
Recent Announcements
Recent Announcements
Y
Y Combinator Blog
Microsoft Security Blog
Microsoft Security Blog
雷峰网
雷峰网
Jina AI
Jina AI
酷 壳 – CoolShell
酷 壳 – CoolShell

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call T...
2026-05-13 · via All Articles on Seeking Alpha

Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call May 12, 2026 8:00 AM EDT

Company Participants

Jessie Yeung - Vice President of Finance, Investor & Public Relations
Ying Huang - CEO & Director
Alan Bash - President of CARVYKTI®
Carlos Santos - Chief Financial Officer
Guowei Fang - President of Research & Development

Conference Call Participants

Terence Flynn - Morgan Stanley, Research Division
Umer Raffat - Evercore ISI Institutional Equities, Research Division
Jessica Fye - JPMorgan Chase & Co, Research Division
Konstantinos Biliouris - Oppenheimer & Co. Inc., Research Division
Etzer Darout - Barclays Bank PLC, Research Division
Eric Schmidt - Cantor Fitzgerald & Co., Research Division
James Shin - Deutsche Bank AG, Research Division
Leonid Timashev - RBC Capital Markets, Research Division
Sean McCutcheon - Raymond James & Associates, Inc., Research Division
Ashwani Verma - UBS Investment Bank, Research Division
Yaron Werber - TD Cowen, Research Division

Presentation

Operator

Good day, and thank you for standing by. Welcome to the Legend Biotech First Quarter 2026 Earnings Conference Call.

[Operator Instructions] Today's conference is being recorded. I will now hand the conference over to your speaker host for today, Jessie Yeung, Vice President of Investor Relations and Finance. Please go ahead. Good morning.

Jessie Yeung
Vice President of Finance, Investor & Public Relations

This is Jessie Yeung, Vice President of Investor Relations and Finance at Legend Biotech. Thank you for joining our conference call today to review our first quarter of 2026 performance.

Prior to this call, we issued a press release announcing our financial results for the quarter. You can find the press release on our IR website at legendbiotech.com. Joining me on today's call are Ying Huang, the company's Chief Executive Officer; Alan Bash, the company's President of CARVYKTI; and Carlos Santos, the company's Chief Financial Officer. Following the prepared remarks, we will open up the call for Q&A. We also have our President of R&D, Guowei Fang, joining the Q&A session.